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Ahstrrrcr. Mass treatments with ivermectin have been undertaken each year since 1987 in an area hyperendemic 
for onchocerciasis in northern Cameroon. The impact of these successive treatments on the incidence of infection in  
humans was evaluated by comparing the prevalence of skin microfilariae (PMF) and the mean micrdfilarial skin 
densities (MFD) observed in 1987 and 1992 in 5-7-year-old children who had never taken the drug but who were 
members of the treated communities. In 1992, the PMF and the MFD in children in this age group who never received 
ivermectin were reduced by 55% and 77%, respectively, in comparison with the values observed in 1987, before the 
first treatment round. These results reflect a pronounced reduction in the intensity of the transmission of O~zchocer-c~~ 
voli~ulirs in the treatment zone. The influence of the ivermectin treatment coverage in the human population, as well 
as the vectorial capacity and the dispersal of the vector blackflies, on the transmission of onchocerciasis is discussed. 
Mass ivermectin treatment of populations infected with 
onchocerciasis brings about a reduction in  the transmission 
of the parasite. This effect has been demonstrated in the 
course of various studies by comparing before and after 
treatment the infection rates in vector blackflies.I4 This im- 
pact on transmission was also demonstrated in an indirect 
manner in Liberia, where two successive treatments of a 
population with ivermectin brought about a decrease in the 
incidence of infection in untreated childreixS 
In  Cameroon, community-wide ivermectin treatments 
have been carried out since 1987 in the North Vina Valley, 
a savanna area endemic for onchocerciasis.' By the end of 
1992, more than 30,000 patients had received at least one 
ivermectin treatment. The purpose of the present study, con- 
ducted in the villages treated since 1987, was to evaluate the 
impact of five successive mass ivermectin treatments of a 
population on the prevalence and the intensity of the infec- 
tion in untreated children belonging to the same community. 
, 
PATIENTS AND METHODS 
Study area. The North Vina Valley lies in the Sudan- 
savanna zone of northern Cameroon between 13'30' and 
15'35'E and 7"20' and SoN. A map of the area has been 
presented in a previous paper.' The valley covers an area of 
13,100 km'. There are two distinct seasons with the rains 
lasting from May to October. The North Vina River rises at 
an elevation of 1,435 meters on the Adamawa Plateau, about 
25 km northwest of the town of Ngaoundere. It flows in an 
easterly direction and after a course of some 314 km joins 
the Mbere River at the boundary between Cameroon and 
Chad to form the West Logone River. The North Vina River 
and the Mbere River are perennial, whereas their tributaries 
flow only during the rainy season. The valley is limited on 
the north and on the south by two ranges of mountains rising 
up to 1,920 meters. In the middle and eastern parts of the 
valley, the villages lay almost exclusively on a road that runs 
on the left bank of the North Vina River. The human pop- 
ulation is sparsely distributed (density less than four persons/ 
km2). The people belong mainly to the Mboum ethnic group. 
The major occupations are subsistence agricultural farming 
and cultivation of cotton. ORSTOM Documentation 
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The North Vina Valley is an area endemic for onchocer- 
ciasis that is part of the vast Vina-Pende-Logone focus, 
which extends across Cameroon, the Central African Repub- 
lic, and Chad. Ophthalmologic studies conducted in this area 
before ivermectin distribution reported high prevalences of 
severe onchocercal eye lesions.'.6 .In the North Vina Valley 
0izclzocrrz.a volvrdr~s is transmitted almost exclusively by 
Sirmrliiriiz ck~~~z i zo . s~~~~z  S.S. and S. ~ i r / m z ¿ i ~ ? ~ . ~  Longitudinal en- 
tomologic studies have shown that transmission of oncho- 
cerciasis in  the study area occurs principally during the rainy 
season.ß 
Study population: description, examination, and treat- 
ment schedules. The study was conducted in five contiguous 
communities situated several kilometers west of the town of 
Touboro, in the eastern part of the valley, on a road that runs 
parallel to the course followed by the river. The villages 
were Bonandika, Man Rigara, Voye, Mbailara, and Ngoumi. 
They were selected because of background information giv- 
ing evidence of high endemicity levels. A total of 3,028 
people were recorded in  these\villages during the nationwide 
census of 1987 (Table I ) ,  a number close to the one recorded 
two years before by the cotton development project. No ex- 
tra, specific census was conducted during the study. Pretreat- 
ment parasitologic examinations of subjects five years of age 
and older, and the first administration of ivermectin, were 
carried out in November 1987 in the five villages using the 
methods described below. The team stayed several days in 
each village to collect the most exhaustive data possible and 
to achieve an optimal treatment coverage. The other com- 
munities of the valley were not treated in 1987. The five 
villages treated in 1987, identified below as the initial treat- 
ment area, were treated again in 1988, six months after the 
first treatment round. The subsequent treatments in these 
communities were given at yearly intervals until 1992. In 
1992, a parasitologic examination of all people was carried 
out just prior to the dosing. A particular effort was made to 
raise to a maximum the participation of children who never 
received ivermectin previously. We report in the present pa- 
per the parasitologic results obtained in 1987 and 1992 in 
children 5-7 years of age who lived in the original treatment 
area and who never took ivermectin. 
In 1988, an initial ivermectin distribution was undertaken 
3 
I 
64 BOUSSINESQ AND OTHERS 
TABLE 1 
Population recorded during the nationwide census of 1987, and pre- 
treatment prevalence of skin microfilariae (PMF), and geometric 
mean microfilarial density (MFD) in the initial treatment area 
Population Number PMF MFD 
Sex census examined (?o) (mhs)* 
Age 
0-4 M 397 O 
F 38 1 O 
Total 778 O 
(years) 
- - 
- - 
- - 
5-9 M 309 103 61.2 4.9 
F 297 129 55.8 2.8 
Total 606 232 58.2 3.6 
10-14 M 
F 
Total 
15-29 M 
F 
Total 
30-49 M 
F 
Total 
250 M 
F 
Total 
2 5  M 
F 
Total 
I10 
98 
208 
315 
485 
800 
216 
23 I 
447 
119 
70 
I89 
1,069 
1,181 
2,250 
101 
76 
177 
290 
314 
604 
180 
I49 
329 
60 
41 
101 
734 
709 
1.443 
88. I 
76.3 
83.1 
97.9 
93.9 
95.9 
97.2 
96.0 
96.7 
98.3 
95.1 
97.0 
91.3 
85.6 
88.5 
29.6 
9.4 
18.4 
1 11.7 
41.4 
67.0 
113.3 
82.7 
98.2 
159.8 
175.7 
165.9 
28.5 
63.9 
43. I 
* m h  = microfilariae pcr skin snip. 
in  29 additional villages situated west of the original treat- 
ment area. This first extension zone extended up to the vil- 
lage of Vongna, located approximately at the middle point 
of the valley. In 1989, the treatment area was extended again 
and ivermectin was distributed to a total of 73 communities, 
including the town of Touboro. During this treatment round, 
the villages located in the western (and upper) part of the 
valley and the area situated east of the original treatment 
zone (up to the boundary between Cameroon and Chad) 
were treated for the first time. In 1990 and 1991, ivermectin 
distribution was restricted to the most severely affected vil- 
lages, and the treatment area extended from the boundary 
between Cameroon and Chad to the village of Lagoye, lo- 
cated about 35 km from the western limit of the original 
treatment area. 
Drug administration. A meeting between the represen- 
tatives of the communities and the distribution team was 
organized three or four days before drug administration to 
mobilize the population. In the smaller villages, ivermectin 
was given in the village chief's home, located at a central 
place in the village. In the larger communities, i.e., with a 
population of more than 1,000 inhabitants, the distribution 
was carried out in several sites corresponding to the village 
chief's and quarter chief's house and occasionally in a 
school. In the initial treatment area, Ngoumi was the only 
village with such a large population. In all villages, the most 
remote residents lived within 1 km of a dosing point, and 
the first treatment was given by a team of one or two phy- 
sicians, two nurses, and two secretaries. During the distri- 
butions carried out in 1987 and 1992 in the initial treatment 
area, the dosing team stayed for three consecutive days be- 
tween 8:00 AM and 6:OO PM at each treatment and exami- 
nation site. The drug was administered at a dose of 150 yg/ 
kg of body weight, taking into account the usual exclusion 
criteria: children less than five years of age, a weight less 
than 15 kg, pregnancy, first month of lactation, jaundice, 
central nervous system disease, and severe clinical illness. 
The full name, sex, age, and weight of every treated person 
was registered every year and the data concerning the chil- 
dren less than 10 years of age were gathered in a file. Thus, 
it was possible to know if a child received a treatment during 
the previous years. The tablets were swallowed by the sub- 
jects in front of the drug dispenser so that the drug could 
not be taken away and given to people ineligible for treat- 
ment. 
Parasitologic examination. Before the first treatment 
round in 1987, a parasitologic examination was carried out 
in the original treatment area in 1,443 subjects five years of 
age and older who came to the ivermectin distribution point 
and agreed to be examined (Table 1). These individuals cor- 
respond to 64.1% of the population five years of age and 
older recorded during the nationwide census of 1987. 
Among the 1,443 subjects examined, 151 were five-, six, 
and seven-year-old children. This sample corresponds to 
36.4% of the children of this age recorded in 1987. Two skin 
snips were taken with a 2-mm Holth corneoscleral punch 
(Storz Instrument GmbH, Heidelberg, Germany) from the 
two iliac crests of each patient. Each biopsy specimen was 
immediately placed in  the well of a microtitration plate con- 
taining 300 p.1 of saline. The plate was then covered with 
Parafilm@ (American Can Company, Greenwich, CT) to re- 
duce evaporation. After incubation for 24 hr, the emerged 
microfilariae were counted under a low-power microscope. 
For each subject, we calculated the individual microfilarial 
load, defined as the arithmetic mean of the microfilarial 
counts from the two skin snips. 
A parasitologic examination using the same method was 
carried out in  1992 in the same area before the sixth iver- 
mectin treatment round among all five-, six-, and seven-year- 
old children who had never received the drug and who came 
to the dosing point for their first treatment. Seventy-three 
children were examined, corresponding to approximately 
15% of the children of this age who lived in the initial treat- 
ment area in 1992. Examinations were not performed in old- 
er children because most of them had received at least one 
dose of ivermectin previously. 
Data analysis. The pretreatment level of endemicity in  
the original treatment area was evaluated by means of two 
parasitologic indices used in the Onchocerciasis Control Pro- 
gamme (OCP) in West Africa, i.e., the age- and sex-stan- 
dardized prevalence of skin microfilariae, and the commu- 
nity microfilarial load (CMFL). The standardized prevalence 
of skin microfilariae was calculated using the age and sex 
distribution in the OCP area.9 The CMFL is the geometric 
mean number of microfilariae per skin snip among adults 20 
years of age and older in the community, including those 
with negative counts. This mean was calculated using the 
log (x + 1) transformation.1° Two indicators have been used 
to describe the level of infection by age and sex: the prev- 
alence of skin microfilariae (PMF) and the geometric mean 
microfilarial density per skin snip (MFD). The MFD were 
calculated using the log(x + 1) transformation, where x is 
the individual microfilarial load. This transformation was 
done to take into account negative microfilarial counts." 
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Treatment coverages during the successive treatment rounds 
were calculated using the data of the nationwide census of 
1987. 
The effect of the community-wide ivermectin treatments 
on the transmission of onchocerciasis was evaluated by com- 
paring parasitologic indices calculated, on the one hand, in 
children 5-7 years old before the first treatment round (in 
1987) and, on the other hand, in children belonging to the 
same age group in  1992 and who had not received any prior 
ivermectin treatment. The PMF and the MFD were calcu- 
lated in the 5-7-year-old children and separately in the five- 
, six-, and seven-year-old children. The Pearson’s chi-square 
test was used to compare the PMF between 1987 and 1992. 
For the MFD, comparisons were carried out using the Stu- 
dent’s t-test. In both tests, the differences were considered 
significant when P < 0.05. 
RESULTS 
Pretreatment endemicity levels in the original treat- 
ment area. The age- and sex-standardized prevalence of 
skin microfilariae in the overall population five years old and 
older was 87.6% prior to the first treatment round. The stud- 
ied community was therefore hyperendemic for onchocer- 
ciasis. The initial CMFL was 85.5 microfilariae per skin snip 
(mfks). In males, the skin microfilarial densities showed a 
rapid increase with age during the first 15 years, and then 
leveled off (Table 1). In females, the microfilarial densities 
increased more gradually with age and reached a maximum 
in those more than 50 years of age. In the 5-9-, 10-14-, and 
15-29-year-old age groups, the mean microfilarial densities 
were about twice as high in males as in females. In older 
age groups, the densities were similar in both sexes. 
Drug coverage. In the original treatment area, a total of 
2,244 and 2,024 persons received ivermectin during the first 
and second treatment rounds, respectively, (Table 2). The 
number of people treated in the younger age groups was 
higher than the number recorded during the nationwide cen- 
sus. Two explanations may be given for this result. It may 
be due to the fact that a proportion of young people living 
in the initial treatment area have not been recorded in the 
villages during the census (some of them are schoolchildren 
in  the nearby town of Touboro). Alternatively, some children 
who have been treated in the villages might have come from 
Touboro, where they actually lived. The number of people 
treated decreased during the three subsequent treatment 
rounds: 1,794, 1,448, and 1,774 persons were treated in 
1989, 1990, and 199 1 ,  respectively. Assuming that about 
25% of the total population cannot receive ivermectin be- 
cause they fall under the exclusion criteria, we can estimate 
that more than 80% of the eligible population in the initial 
treatment area were treated during the first and second treat- 
ment rounds. No significant migration occurred in the initial 
treatment area during the period of the study. Assuming that 
the annual rate of increase of the population in the study 
area corresponded to the one observed in similar regions in 
northern Cameroon (approximately 2.5%), we can estimate 
that the drug coverage obtained between 1989 and 1991 
ranged from 60% to 80%. 
A detailed analysis of the sex and age structure of the 
population treated during the successive rounds showed that 
TABLE 2 
Number of patients treated, according to sex and age, in the initial 
treatment area between 1987 and 1991 
Number of pxtients lrcared 
1987 1988 1989 1990 1991 
Age 
(years) SCX 
5-9 
10-14 
15-29 
30-49 
250 
2 5  
M 305 
F 318 
Total 623 
F 127 
Total 293 
M 3 65 
F 392 
Total 757 
M 213 
F 186 
Total 399 
M 82 
F 90 
Total 172 
M ,131 
F , I  13 
Total 2,244 
M *, 166 
~ 
278 
255 
533 
154 
I o9 
263 
358 
356 
714 
202 
170 
372 
74 
68 
I42 
1,066 
958 
2,024 
228 
203 
43 1 
I69 
I17 
286 
366 
I85 
55 1 
245 
142 
387 
78 
61 
139 
1,086 
708 
1,794 
204 
234 
438 
I09 
52 
161 
267 
145 
412 
197 
114 
31 I 
70 
56 
126 
847 
60 I 
1,448 
27 1 
292 
563 
I24 
96 
220 
313 
153 
466 
260 
I46 
406 
53 
66 
1 I9 
1 ,o2 I 
753 
1,774 
the reduction in treatment coverage observed since 1989 
concerned principally females 15-29 years of age. In 1987 
and 1988, 392 and 356 subjects of this group, respectively, 
received ivermectin, whereas less than 200 women (average 
number 160) were treated during the following three rounds. 
In contrast, participation decreased only slightly in men 15- 
29 years of age. Between 1989 and 1991, an average number 
of 315 patients belonging to this group was treated every 
year, compared with 365 and 358 in 1987 and 1988, respec- 
tively. In children 5-9 years old, adolescents 10-14 years 
old, and people 50 years old and older, the decrease of par- 
ticipation during the three last treatment rounds was similar 
(about 25%) when compared with the number of subjects 
treated in 1987. The most regular attendance during the suc- 
cessive treatments was observed in the 30-49-year-old age 
group. The average participation of these individuals during 
the 1989-1991 distributions was reduced by only 10% in 
comparison with the number treated in 1987. 
Evolution of parasitologic indices in untreated children 
between 1987 and 1992. A total of 151 children 5-7 years 
of age was examined before the first treatment round and 73 
children of the same age group were examined after the 
community had received five successive treatments (Table 
When one considers the total number of children exam- 
ined and treated, the PMF decreased from 52.3% in 1987 to 
23.3% in 1992 (reduction of 55.4%). This decrease is Sig- 
nificant (P < 0.0001). When evaluated by age, the decrease 
in the PMF is significant for the five-year-old (P  < 0.01) 
and the seven-year-old children (P  < 0.01), but not for six- 
year-old children (P  > 0.10). 
Between 1987 and 1992, the MFD in the total number of 
children examined and treated decreased from 3.1 to 0.7 mf/ 
ss (reduction of 77.4%). This decrease is significant ( P  < 
IO-’). AS with the PME the MFD decreased significantly in  
the five-year-old ( P  < 0.05) and the seven-year-old children 
3). 
. 
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TABLE 3 
Prevalence of skin microfilariae (PMF) and geometric mean microfilarial density (MFD) in untreated children before (1987) and after the 
community received five treatments (1992) with ivermectin:v 
Comparison of 1987 with 1992 
No. PMF MFO No. PMF MFD PMF M FD 
snipped (%) (mf/ss) snipped (%) (mf/ss) (%It  (m f/ss)t 
1987 1992 
Age 
(years) 
5 47 48.9 1.7 22 13.6 0.3 <o.o 1 <0.05 
6 54 44.4 2.6 38 28.9 I .2 NS NS 
7 50 64.0 4.7 13 23.1 0.2 <O.OI <o.o I 
Total 151 52.3 3.1 73 23.3 0.7 <o.ooo I <IO-’  
* mf/ss = microfilariae per skin snip: NS = not significant. 
t P values. 
( P  < 0.01), but no significant change in the MFD was ob- 
served in  six-year-old children ( P  > 0.10). 
DISCUSSION 
In the North Vina Valley, repeated treatments with iver- 
mectin brought about a significant decrease in the overall 
level of onchocerciasis infection in untreated children. When 
evaluated by age, this decrease was significant for the 5-7- 
year-old children, but not for the six-year-old ones. This is 
due to the fact that the only three children with high micro- 
filarial loads in 1992 (defined as more than 50 mflss) were 
clustered in  the six-year-old age group. 
A study comparable with the one carried out in northern 
Cameroon was conducted in Liberia in an area endemic for 
onchocerciasis where the vector is S. yc1hei7.se.~ Two treat- 
ments with ivermectin were administered to the residents of 
a rubber plantation with a one-year interval. Before the first 
treatment, the prevalence of skin microfilariae in five-year- 
old children was 23.9%. One year after the second distri- 
bution of ivermectin, the prevalence was 19.0% (reduction 
of 21%) in children of the same age and who had not re- 
ceived any treatment. This decrease was significant. 
In northern Cameroon, the decrease in the prevalence of 
infection in children between the ages of five and seven 
years is much greater than that observed in Liberia. This 
difference is probably linked to the number of doses admin- 
istered. In Liberia, the parasitologic examinations of untreat- 
ed children were conducted after two treatment rounds, 
while in Cameroon we evaluated the effect of five successive 
treatments. Previous studies have shown that an initial treat- 
ment with ivermectin brings about a dramatic decrease in 
skin microfilarial densities, whereas subsequent doses are 
followed by more gradual reductions.12-1s The effect of iver- 
mectin on the prevalence of skin microfilariae was also doc- 
umented, and the figures show a progressive reduction in 
this indice after successive From these observa- 
tions, we may assume that the reservoir of skin microfilariae 
available to the blackflies has continued to be reduced after 
the third treatment round in the Vina Valley, and that this 
progressive decrease led to an additional reduction in the 
transmission of onchocerciasis between 1989 and 1992. 
The lower impact of ivermectin treatments on transmis- 
sion in Liberia may also be linked to differences in the bi- 
ology of the vectors: it is possible that in Liberia the black- 
flies coming from zones close to the treatment area may have 
maintained a pronounced transmission of onchocerciasis.4 In 
northern Cameroon, this phenomenon of reinvasion is lim- 
ited, on the one hand, by the presence of a range of moun- 
tains that geographically isolates the Vina Valley, and, on 
the other hand, by the fact that the vegetation is not favor- 
able to wide dispersal of the blackflies. Moreover, the treat- 
ment area in the Vina Valley was extended widely after 
1987. It is likely that these extensions led to an additional 
reduction in the infection rates of blackflies in the original 
area after the second treatment round. 
Several factors make the results from northern Cameroon 
remarkable. First, in  the Vina Valley, the coverage of the 
population that was achieved during the second and the sub- 
sequent treatment rounds was clearly less than that obtained 
in Liberia, where 97% of the eligible population was treated. 
Despite this, an important reduction in the transmission of 
the parasite has been achieved. This is probably due to the 
fact that in the Vina Valley, the treatment coverage during 
the first treatment round was high (more than 90% of the 
eligible population) and therefore this initial dose brought 
about a great reduction in the transmission of onchocerciasis 
infection in the original treated area. Thereafter, the micro- 
filarial densities in the subjects who missed subsequent 
rounds increased to a higher level than in those who were 
treated, but previous studies have shown that this increase 
is very S I O W . ~ ~ . ~ ~  In the original treatment area in the Vina 
Valley, the reduction of the microfilarial load was not sig- 
nificantly different (between 93 and 97% from the initial 
value) in people who received three, four, or five doses in a 
period of five years.I5 These observations could explain why 
a treatment coverage of the order of 60-7070 is sufficient to 
produce a marked reduction of the transmission of oncho- 
cerciasis. Moreover, the reduction in treatment coverage ob- 
served since I989 concerned principally the females 15-29 
years of age. The pretreatment mean microfilarial densities 
in this population subgroup were not very high in compar- 
ison with the densities observed in males and in older fe- 
males (Table l). We may, therefore, assume that in the Vina 
Valley, the females 15-29 years of age contributed relatively 
little to the transmission of onchocerciasis and that the de- 
crease in coverage in this group since 1989 had only a slight 
influence on the impact of the successive treatment rounds 
on transmission. The fact that treatment coverage decreased 
mainly for the 15-29-year-old females may be due to two 
factors. First, the clinical symptoms of onchocerciasis, which 
are related to the microfilarial load, are relatively low in this 
subgroup. Second, although we tried to avoid this phenom- 
enon by staying in each village for a long time, the 15-29- 
year-old females were very busy with housekeeping activi- 
ties, and therefore less disposed to come to the distribution 
I V E R M E C T I N  A N D  ONCHOCERCA T R A N S M I S S I O N  I N  C A M E R O O N  67 
points. These factors may explain that this subgroup did not 
come for treatment as assiduously as the other people after 
the first two treatment rounds. 
Second, the vectors of onchocerciasis in northern Came- 
roon belong to S. dciinrzosuin S.S. and S. sirbunuin species. 
Among these species exists a phenomenon that limits the 
passage of microfilariae in the haemocele: the proportion of 
microfilariae that survive and develop to become infective 
larvae decreases as more microfilariae are ingested.I8 Con- 
versely, S. darnizosiinz S.S. and S. sirbnrzurn may be able to 
maintain transmission even when skin microfilarial densities 
are low. Because of this phenomenon, one would expect the 
impact of mass ivermectin treatments on the transmission of 
the parasite to be limited in areas where onchocerciasis is 
transmitted by these species. This phenomenon of limitation 
is lower among S. yafzerzse as well as among other vectors 
in the forest regions of West Africa. The incidence of onch- 
ocerciasis can therefore be expected to decrease to a greater 
extent and more rapidly in the areas where onchocerciasis is 
not transmitted by S. dumizosurn. S.S. and S. sirbcinurn. 
Thus, i t  seems that despite some unfavorable factors, the 
impact of repeated mass treatments with ivermectin on the 
transmission of onchocerciasis can be quite pronounced. 
This effect will be greater as the treatment area is expanded 
to include more communities in  the surrounding area. 
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